Casodex/Zoladex Biomarkers in Localised Prostate Cancer
Phase 4
Completed
- Conditions
- Prostate Cancer
- Registration Number
- NCT00293696
- Lead Sponsor
- Tampere University
- Brief Summary
To evaluate anti-androgen (bicalutamide) induced biological and molecular changes in prostate comparison to chemical castration induced (goserelin) ones
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
- Histologically confirmed localised prostate biopsy specimen that contains sufficient tumour for evaluation of cell proliferation and apoptosis markers
- Patients who are scheduled for radical prostatectomy with curative intents
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Proliferation by Ki67, apoptosis marker (TUNEL assay), Gleason score
- Secondary Outcome Measures
Name Time Method (novel) genomic transcripts expression of known androgen-regulated genes, biomarkers of apoptotic pathway,
Trial Locations
- Locations (1)
TUCH
🇫🇮Tampere, Finland
TUCH🇫🇮Tampere, Finland